Kevin Outterson is the Executive Director at CARB-X and the Austin B. Fletcher Professor at Boston University School of Law.
CARB-X is the world’s leading non-profit public-private partnership that supports the early-stage development of innovative products to prevent, diagnose and treat the syndromes with the greatest global morbidity and mortality caused by the most dangerous drug-resistant bacteria identified by the WHO and CDC priority lists. Kevin founded CARB-X in 2016. Since then, CARB-X has received more than US$800 million in funding and accelerated 100+ innovative products in over a dozen countries.
The funders of CARB-X include the Biomedical Advanced Research and Development Authority (BARDA) within the Administration for Strategic Preparedness and Response (ASPR) of the U.S. Department of Health and Human Services (HHS); the U.S. National Institute of Allergy and Infectious Diseases (NIAID); Wellcome, Germany’s Federal Ministry of Education and Research (BMBF), the United Kingdom’s Global Antimicrobial Resistance Innovation Fund (GAMRIF), the Public Health Agency of Canada (PHAC), the Bill & Melinda Gates Foundation, and the Novo Nordisk Foundation.
Kevin’s research focuses on global pharmaceutical markets, particularly antibiotics and other antimicrobials that can degrade in usefulness over time through resistance. His publications may be found at Google Scholar. He served as the senior author on many key research reports on antibiotic innovation, including reports by Chatham House, Eastern Research Group (ERG), DRIVE-AB, and the Lancet Commission. Kevin was given the 2015 Leadership Award by Alliance for Prudent Use of Antibiotics for his research and advocacy work. He has testified before U.S. Congress, parliamentary working groups, and the WHO as well as several State Legislatures.